Paper41597449
Mechanisms of Pseudomonas aeruginosa Resilience Against Antibiotic Treatment and Outlooks of Emerging Treatment Strategies.
Krūmiņa A and 5 others. Medicina (Kaunas), 2026. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Mechanisms of Pseudomonas aeruginosa Resilience Against Antibiotic Treatment and Outlooks of Emerging Treatment Strategies. Papers, record 41597449. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41597449
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Mechanisms of Pseudomonas aeruginosa Resilience Against Antibiotic Treatment and Outlooks of Emerging Treatment Strategies.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Pseudomonas aeruginosa | Major topic |
| Anti-Bacterial Agents | Major topic |
| Pseudomonas Infections | Major topic |
| Humans | |
| Quorum Sensing | |
| Biofilms | |
| Drug Resistance, Bacterial |
Source PubMed
References185
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36857468 | Mechanisms of iron homeostasis in Pseudomonas aeruginosa and emerging therapeutics directed to disrupt this vital process. | Microb Biotechnol | 2023 | https://conductscience.org/library/papers/36857468 | PubMed |
| 2 | 23620179 | Pseudomonas aeruginosa: new insights into pathogenesis and host defenses. | Pathog Dis | 2013 | https://conductscience.org/library/papers/23620179 | PubMed |
| 3 | 30852658 | Natural quorum sensing inhibitors effectively downregulate gene expression of Pseudomonas aeruginosa virulence factors. | Appl Microbiol Biotechnol | 2019 | https://conductscience.org/library/papers/30852658 | PubMed |
| 4 | 34961221 | Glycyrrhiza glabra (Licorice): A Comprehensive Review on Its Phytochemistry, Biological Activities, Clinical Evidence and Toxicology. | Plants (Basel) | 2021 | https://conductscience.org/library/papers/34961221 | PubMed |
| 5 | 28649396 | Eradication of Pseudomonas aeruginosa biofilms and persister cells using an electrochemical scaffold and enhanced antibiotic susceptibility. | NPJ Biofilms Microbiomes | 2016 | https://conductscience.org/library/papers/28649396 | PubMed |
| 6 | 33593280 | Pseudomonas aeruginosa device associated - healthcare associated infections and its multidrug resistance at intensive care unit of University Hospital: polish, 8.5-year, prospective, single-centre study. | BMC Infect Dis | 2021 | https://conductscience.org/library/papers/33593280 | PubMed |
| 7 | 37627724 | The Art of War with Pseudomonas aeruginosa: Targeting Mex Efflux Pumps Directly to Strategically Enhance Antipseudomonal Drug Efficacy. | Antibiotics (Basel) | 2023 | https://conductscience.org/library/papers/37627724 | PubMed |
| 8 | 19192306 | Pseudomonas aeruginosa vesicles associate with and are internalized by human lung epithelial cells. | BMC Microbiol | 2009 | https://conductscience.org/library/papers/19192306 | PubMed |
| 9 | 22363222 | Tasco®: a product of Ascophyllum nodosum enhances immune response of Caenorhabditis elegans against Pseudomonas aeruginosa infection. | Mar Drugs | 2012 | https://conductscience.org/library/papers/22363222 | PubMed |
| 10 | 28289035 | WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones. | Antimicrob Agents Chemother | 2017 | https://conductscience.org/library/papers/28289035 | PubMed |
| 11 | 34683362 | Towards Advances in Medicinal Plant Antimicrobial Activity: A Review Study on Challenges and Future Perspectives. | Microorganisms | 2021 | https://conductscience.org/library/papers/34683362 | PubMed |
| 12 | 36726844 | Recent Approaches for Downplaying Antibiotic Resistance: Molecular Mechanisms. | Biomed Res Int | 2023 | https://conductscience.org/library/papers/36726844 | PubMed |
| 13 | 20196657 | Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. | J Infect Dis | 2010 | https://conductscience.org/library/papers/20196657 | PubMed |
| 14 | 39151738 | Antibacterial and antibiofilm effect of Zinc Oxide nanoparticles on P. aeruginosa variants isolated from young patients with cystic fibrosis. | Microb Pathog | 2024 | https://conductscience.org/library/papers/39151738 | PubMed |
| 15 | 35884138 | Aminoglycoside-Modifying Enzymes Are Sufficient to Make Pseudomonas aeruginosa Clinically Resistant to Key Antibiotics. | Antibiotics (Basel) | 2022 | https://conductscience.org/library/papers/35884138 | PubMed |
| 16 | 29322006 | Attenuation of quorum-sensing-dependent virulence factors and biofilm formation by medicinal plants against antibiotic resistant Pseudomonas aeruginosa. | J Tradit Complement Med | 2018 | https://conductscience.org/library/papers/29322006 | PubMed |
| 17 | 18379232 | Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. | Crit Care Med | 2008 | https://conductscience.org/library/papers/18379232 | PubMed |
| 18 | 12654672 | MexXY-OprM efflux pump is necessary for a adaptive resistance of Pseudomonas aeruginosa to aminoglycosides. | Antimicrob Agents Chemother | 2003 | https://conductscience.org/library/papers/12654672 | PubMed |
| 19 | 41163953 | Antimicrobial Mechanisms of Metal-Based Nanomaterials. | Int J Nanomedicine | 2025 | https://conductscience.org/library/papers/41163953 | PubMed |
| 20 | 40585316 | Combination of phages and antibiotics with enhanced killing efficacy against dual-species bacterial communities in a three-dimensional lung epithelial model. | Biofilm | 2025 | https://conductscience.org/library/papers/40585316 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42876396 | A generalizable method for the purification and biophysical characterization of bacterial membrane receptors. | Protein Sci | 2026 | https://conductscience.org/library/papers/42876396 | PubMed |
| 42726449 | Phenotypic characterization of raw milk-associated Pseudomonas spp.: biofilm formation across different temperatures, antimicrobial resistance, and cytotoxicity. | Braz J Microbiol | 2026 | https://conductscience.org/library/papers/42726449 | PubMed |
| 42663771 | Evaluation of phytochemical-mediated inhibition of the efflux pump in Pseudomonas aeruginosa PAO1. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42663771 | PubMed |
| 42451116 | Probiotic-Plant Bioactive Synergy in Gut Health: Mechanisms, Antimicrobial Activity, and Translational Challenges. | Nutrients | 2026 | https://conductscience.org/library/papers/42451116 | PubMed |
| 42450264 | Combining Diclofenac and Cannabidiol to Enhance the Antibacterial Capacity of Nonantibiotic Drugs Through Potentiation. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42450264 | PubMed |
| 42113464 | Integrating resistance biology, virulence networks, and precision therapeutics against multidrug-resistant Pseudomonas aeruginosa. | Infection | 2026 | https://conductscience.org/library/papers/42113464 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41597449
GET https://conductscience.org/api/papers/v1/41597449/references?page=2